Pinchas Cohen

Pacific Palisades, CA, United States of America

Pinchas Cohen

This inventor holds 10 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: University of California, University of Southern California, Albert Einstein College of Medicine. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pinchas Cohen. Retrieved from https://idiyas.com/inventor/pinchas-cohen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 29(Granted Patents)


Location History:

  • Pacific Palisades, CA (US) (2011 - 2019)
  • Los Angeles, CA (US) (2021 - 2023)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Mind of Pinchas Cohen

Introduction

Pinchas Cohen is a prominent inventor based in Pacific Palisades, California, with a remarkable portfolio of eight patents. His groundbreaking work focuses primarily on therapeutic advancements related to diabetes and obesity, showcasing his dedication to medical innovation and public health.

Latest Patents

Among his noteworthy contributions, Cohen's latest patents revolve around MENTSH analogs as therapeutics for diabetes, obesity, and their associated diseases and complications. These patents detail the discovery of a novel, mitochondrial-encoded open reading frame that produces a new mitochondrial peptide. This peptide is crucial as a specific small nucleotide polymorphism within the ND-Two subunit disrupts its expression, leading to increased obesity and diabetes prevalence, particularly among certain ethnic groups. In vitro studies have shown that administering this peptide enhances insulin secretion, reduces fat accumulation, and improves glucose uptake in muscle cells. Moreover, generated antibodies can detect peptide deficiency and SNP presence, aiding diagnostic practices. In vivo studies indicate that this peptide improves glucose tolerance, offering new therapeutic pathways for diabetes and obesity treatment. Additionally, synthetic analogs have been engineered to enhance or modulate the activity of the natural peptide, further broadening its therapeutic potential.

Career Highlights

Cohen has built an impressive career in academia, working with prestigious institutions such as the University of California and the University of Southern California. His dedication to scientific research and innovation has solidified his reputation in the field of biomedical research, particularly in developing novel therapies for metabolic diseases.

Collaborations

Throughout his career, Cohen has collaborated with esteemed colleagues, including Kuk-Wha Lee and Changhan Lee. These partnerships have fostered a rich environment for innovation and have contributed significantly to the success of his research efforts.

Conclusion

Pinchas Cohen's innovative contributions to the fields of diabetes and obesity therapy reflect his expertise and commitment to addressing critical health challenges. Through his patents and collaborative research, Cohen continues to pave the way for new therapeutics that can significantly improve the quality of life for individuals affected by these prevalent conditions. His work, driven by scientific inquiry and dedication, remains at the forefront of medical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…